EUVIMEDEUVIMED entdecken
Crossref

Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1

Yasuhiro Matsuura, Takayuki Manabe, Tomoko Ohkubo, Masaya Kanda, Kuninori Iwayama, Naoya Kamiyama, Masayuki Chuma, Yoshikazu Tasaki

Biological and Pharmaceutical Bulletin · 2026

DOI: 10.1248/bpb.b26-00348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2026. Verfasst von Yasuhiro Matsuura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy & Pharmacology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan. Hauptthemen laut MEDLINE: Meloxicam, Myeloid Cell Leukemia Sequence 1 Protein, Neuroprotective Agents. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeloxicamMyeloid Cell Leukemia Sequence 1 ProteinNeuroprotective Agents1-Methyl-4-phenylpyridiniumHumansProto-Oncogene Proteins c-aktCell Line, TumorCell SurvivalPhosphatidylinositol 3-KinaseSignal TransductionProto-Oncogene Proteins c-bcl-2NeuronsPhosphatidylinositol 3-KinasesApoptosis

Stichwörter der Autor:innen

1-methyl-4-phenylpyridiniumParkinson’s diseasemeloxicammyeloid cell leukemia 1neuroprotective effect

Substanzen

1-Methyl-4-phenylpyridiniumMeloxicamMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-aktNeuroprotective AgentsMCL1 protein, humanPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-bcl-2Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Hospital Pharmacy & Pharmacology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
  • Department of Nursing, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
  • Department of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo 006-8585, Japan.

Zitieren

APA

Matsuura, Y., Manabe, T., Ohkubo, T., Kanda, M., Iwayama, K., Kamiyama, N., Chuma, M., & Tasaki, Y. (2026). Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b26-00348

Vancouver

Matsuura Y, Manabe T, Ohkubo T, Kanda M, Iwayama K, Kamiyama N, et al. Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1. Biological and Pharmaceutical Bulletin. 2026. doi:10.1248/bpb.b26-00348

BibTeX
@article{Matsuura2026,
  author = {Matsuura, Yasuhiro and Manabe, Takayuki and Ohkubo, Tomoko and Kanda, Masaya and Iwayama, Kuninori and Kamiyama, Naoya and Chuma, Masayuki and Tasaki, Yoshikazu},
  title = {Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.1248/bpb.b26-00348}
}
Kostenlos starten →